An engineered novel lentivector specifically transducing dendritic cells and eliciting robust HBV-specific CTL response by upregulating autophagy in T cells.
- 0
Dendritic cells (DCs) play a predominant function in initiating cell immune responses. Right here we generated a DC-targeting lentiviral vector (LVDC-UbHBcAg-LIGHT) and evaluated its capability to elicit HBV-specific cytotoxic T lymphocyte (CTL) responses. DC-SIGN-mediated particular transduction utilizing this assemble was confirmed in DC-SIGN-expressing 293T cells and ex vivo-cultured bone marrow cells.
LVDC-UbHBcAg-LIGHT-loaded DCs have been extremely efficient in inducing HBV-specific CTLs. Mechanistic research demonstrated autophagy blocking led to a big improve in apoptosis and apparent inhibition of CD8 + T cells entry into S-phase, correspondingly attenuated LVDC-UbHBcAg-LIGHT-loaded DC-induced T cell responses.
This remark was supported by accumulation of pro-apoptotic proteins and the principle detrimental cell cycle regulator-CDKN1B that in any other case can be degraded in activated T cells the place autophagy preferentially occured. Our findings revealed an vital function of autophagy within the activation of T cells and recommended LVDC-UbHBcAg-LIGHT could probably be used as a therapeutic technique to fight persistent HBV an infection with greater safety.
Lentivector Producer Cell Traces with Stably Expressed Vesiculovirus Envelopes.
Retroviral and lentiviral vectors typically use the envelope G protein from the vesicular stomatitis virus Indiana pressure (VSVind.G). Nevertheless, lentivector producer cell traces that stably specific VSVind.G haven’t been reported, presumably due to its cytotoxicity, stopping easy scale-up of vector manufacturing.
Apparently, we confirmed that VSVind.G and different vesiculovirus G from the VSV New Jersey pressure (VSVnj), Cocal virus (COCV), and Piry virus (PIRYV) could possibly be constitutively expressed and supported lentivector manufacturing for as much as 10 weeks.
All G-enveloped particles have been strong, permitting focus and freeze-thawing. COCV.G and PIRYV.G have been resistant to enhance inactivation, and, utilizing chimeras between VSVind.G and COCV.G, the determinant for complement inactivation of VSVind.G was mapped to amino acid residues 136-370. Clonal packaging cell traces utilizing COCV.G could possibly be generated; nonetheless, throughout makes an attempt to determine LV producer cells, vector superinfection was noticed following the introduction of a lentivector genome.
This could possibly be prevented by culturing the cells with the antiviral drug nevirapine. Instead countermeasure, we demonstrated that useful lentivectors could possibly be reconstituted by admixing supernatant from steady cells producing unenveloped virus with supernatant containing envelopes harvested from cells stably expressing VSVind.G, COCV.G, or PIRYV.G.
Microgels produced utilizing microfluidic on-chip polymer mixing for managed launched of VEGF encoding lentivectors.
Alginate hydrogels are broadly used as supply autos as a consequence of their means to encapsulate and launch a variety of cargos in a delicate and biocompatible method. The discharge of encapsulated therapeutic cargos might be promoted or stunted by adjusting the hydrogel physiochemical properties. Nevertheless, the discharge from such techniques is commonly skewed in direction of burst-release or prolonged retention.
To handle this, we hypothesized that the general magnitude of burst launch could possibly be adjusted by combining microgels with distinct properties and launch conduct. Microgel suspensions have been generated utilizing a course of we have now termed on-chip polymer mixing to yield composite suspensions of a variety of microgel formulations.
On this method, we studied how alginate share and degradation relate to the discharge of lentivectors. Whereas modifications in alginate share had a minimal impression on lentivector launch, microgel degradation led to a 3-fold improve, and close to full launch, over 10 days.
Moreover, by controlling the quantity of degradable alginate current inside microgels the relative fee of launch might be adjusted. A degradable formulation of microgels was used to ship vascular endothelial development issue (VEGF)-encoding lentivectors within the chick chorioallantoic membrane (CAM) assay and yielded a proangiogenic response compared to the identical lentivectors delivered in suspension. The utility of blended microgel suspensions could present an particularly interesting platform for the supply of lentivectors or equally sized therapeutics.
Diminished Reminiscence T-Cell Enlargement Resulting from Delayed Kinetics of Antigen Expression by Lentivectors.
Reminiscence CD8(+) T lymphocytes play a central function in protecting immunity. In try to extend the frequencies of reminiscence CD8(+) T cells, repeated immunizations with viral vectors are usually explored. Lentivectors have emerged as a robust vaccine modality with comparatively low pre-existing and anti-vector immunity, thus, regarded as superb for reinforcing reminiscence T cells.
Nonetheless, we discovered that lentivectors elicited diminished secondary T-cell responses that didn’t exceed these obtained by priming. This was not because of the presence of anti-vector immunity, as restricted secondary responses have been additionally noticed following heterologous prime-boost immunizations.
By dissecting the mechanisms concerned on this course of, we exhibit that lentivectors set off exceptionally gradual kinetics of antigen expression, whereas optimum activation of lentivector-induced T cells relays on sturdy expression of the antigen.
These qualities hamper secondary responses, since lentivector-encoded antigen is quickly cleared by major cytotoxic T cells that restrict its presentation by dendritic cells. Certainly, blocking antigen clearance by cytotoxic T cells by way of FTY720 remedy, totally restored antigen presentation.
Taken collectively, whereas low antigen expression is anticipated throughout secondary immunization with any vaccine vector, our outcomes reveal that the intrinsic delayed expression kinetics of lentiviral-encoded antigen, additional dampens secondary CD8(+) T-cell growth.
Breast most cancers vaccines delivered by dendritic cell-targeted lentivectors induce potent antitumor immune responses and defend mice from mammary tumor development.
Breast most cancers immunotherapy is a potent remedy choice, with antibody therapies akin to trastuzumab rising 2-year survival charges by 50%. Nevertheless, lively immunotherapy via vaccination has usually been clinically ineffective.
One potential technique of enhancing vaccine remedy is by delivering breast most cancers antigens to dendritic cells (DCs) for enhanced antigen presentation. To perform this in vivo, we pseudotyped lentiviral vector (LV) vaccines with a modified Sindbis Virus glycoprotein in order that they might ship genes encoding the breast most cancers antigen alpha-lactalbumin (Lalba) or erb-b2 receptor tyrosine kinase 2 (ERBB2 or HER2) on to resident DCs.
We hypothesized that using these DC-targeting lentiviral vectors asa breast most cancers vaccine might result in an improved immune response towards self-antigens present in breast most cancers tumors. Certainly, single injections of the vaccine vectors have been capable of amplify antigen-specific CD8T cells 4-6-fold over naïve mice, just like the perfect revealed vaccine regimens.
Immunization of those mice fully inhibited tumor development in a overseas antigen atmosphere (LV-ERBB2 in wildtype mice), and it decreased the speed of tumor development in a self-antigen atmosphere (LV-Lalba in wildtype or LV-ERBB2 in MMTV-huHER2 transgenic).
KRTAP5-10 - Human, 4 unique 29mer shRNA constructs in lentiviral GFP vector |
|||
| TL319432 | Origene Technologies GmbH | 5 µg/vial | Ask for price |
KRTAP5-11 - Human, 4 unique 29mer shRNA constructs in lentiviral GFP vector |
|||
| TL319435 | Origene Technologies GmbH | 5 µg/vial | Ask for price |
KRTAP5-2 - Human, 4 unique 29mer shRNA constructs in lentiviral GFP vector |
|||
| TL318595 | Origene Technologies GmbH | 5 µg/vial | Ask for price |
KRTAP5-5 - Human, 4 unique 29mer shRNA constructs in lentiviral GFP vector |
|||
| TL320780 | Origene Technologies GmbH | 5 µg/vial | Ask for price |
KRTAP5-9 - Human, 4 unique 29mer shRNA constructs in lentiviral GFP vector |
|||
| TL319428 | Origene Technologies GmbH | 5 µg/vial | Ask for price |
KRTAP5-8 - Human, 4 unique 29mer shRNA constructs in lentiviral GFP vector |
|||
| TL319429 | Origene Technologies GmbH | 5 µg/vial | Ask for price |
KRTAP5-3 - Human, 4 unique 29mer shRNA constructs in lentiviral GFP vector |
|||
| TL319430 | Origene Technologies GmbH | 5 µg/vial | Ask for price |
KRTAP5-6 - Human, 4 unique 29mer shRNA constructs in lentiviral GFP vector |
|||
| TL319433 | Origene Technologies GmbH | 5 µg/vial | Ask for price |
KRTAP5-7 - Human, 4 unique 29mer shRNA constructs in lentiviral GFP vector |
|||
| TL319434 | Origene Technologies GmbH | 5 µg/vial | Ask for price |
Krtap5-1 - Mouse, 4 unique 29mer shRNA constructs in lentiviral GFP vector |
|||
| TL502832 | Origene Technologies GmbH | 5 µg/vial | Ask for price |
Krtap5-2 - Mouse, 4 unique 29mer shRNA constructs in lentiviral GFP vector |
|||
| TL504572 | Origene Technologies GmbH | 5 µg/vial | Ask for price |
KRTAP5-1 - Human, 4 unique 29mer shRNA constructs in lentiviral GFP vector |
|||
| TL311826 | Origene Technologies GmbH | 5 µg/vial | Ask for price |
Krtap5-5 - Mouse, 4 unique 29mer shRNA constructs in lentiviral GFP vector |
|||
| TL514898 | Origene Technologies GmbH | 5 µg/vial | Ask for price |
KRTAP5-13P Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV-C-term-HA) |
|||
| LV730662 | ABM | 1.0 ug DNA | Ask for price |
KRTAP5-14P Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV-C-term-HA) |
|||
| LV730668 | ABM | 1.0 ug DNA | Ask for price |
KRTAP5-13P Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV-GFP-2A-Puro) |
|||
| LV730663 | ABM | 1.0 ug DNA | Ask for price |
KRTAP5-13P Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV-RFP-2A-Puro) |
|||
| LV730664 | ABM | 1.0 ug DNA | Ask for price |
KRTAP5-14P Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV-GFP-2A-Puro) |
|||
| LV730669 | ABM | 1.0 ug DNA | Ask for price |
KRTAP5-14P Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV-RFP-2A-Puro) |
|||
| LV730670 | ABM | 1.0 ug DNA | Ask for price |
KRTAP19-4 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV) |
|||
| LV706161 | ABM | 1.0 ug DNA | EUR 540 |
KRTAP19-4 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV706165 | ABM | 1.0 ug DNA | EUR 540 |
KRTAP1-4 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV) |
|||
| LV730643 | ABM | 1.0 ug DNA | Ask for price |
KRTAP1-4 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV730647 | ABM | 1.0 ug DNA | Ask for price |
KRTAP19-4 Lentiviral Vector (Human) (EF1a) (pLenti-GIII-EF1a) |
|||
| LV706166 | ABM | 1.0 ug DNA | EUR 540 |
KRTAP1-4 Lentiviral Vector (Human) (EF1a) (pLenti-GIII-EF1a) |
|||
| LV730648 | ABM | 1.0 ug DNA | Ask for price |
KRTAP19-4 - Human, 4 unique 29mer shRNA constructs in lentiviral GFP vector |
|||
| TL319447 | Origene Technologies GmbH | 5 µg/vial | Ask for price |
KRTAP12-4 - Human, 4 unique 29mer shRNA constructs in lentiviral GFP vector |
|||
| TL319455 | Origene Technologies GmbH | 5 µg/vial | Ask for price |
Krtap10-4 - Mouse, 4 unique 29mer shRNA constructs in lentiviral GFP vector |
|||
| TL518847 | Origene Technologies GmbH | 5 µg/vial | Ask for price |
Krtap19-4 - Mouse, 4 unique 29mer shRNA constructs in lentiviral GFP vector |
|||
| TL519614 | Origene Technologies GmbH | 5 µg/vial | Ask for price |
KRTAP10-4 - Human, 4 unique 29mer shRNA constructs in lentiviral GFP vector |
|||
| TL307900 | Origene Technologies GmbH | 5 µg/vial | Ask for price |
KRTAP13-4 - Human, 4 unique 29mer shRNA constructs in lentiviral GFP vector |
|||
| TL303610 | Origene Technologies GmbH | 5 µg/vial | Ask for price |
KRTAP19-4 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV-C-term-HA) |
|||
| LV706162 | ABM | 1.0 ug DNA | EUR 540 |
KRTAP1-4 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV-C-term-HA) |
|||
| LV730644 | ABM | 1.0 ug DNA | Ask for price |
KRTAP19-4 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV-GFP-2A-Puro) |
|||
| LV706163 | ABM | 1.0 ug DNA | EUR 609.6 |
KRTAP19-4 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV-RFP-2A-Puro) |
|||
| LV706164 | ABM | 1.0 ug DNA | EUR 609.6 |
KRTAP1-4 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV-GFP-2A-Puro) |
|||
| LV730645 | ABM | 1.0 ug DNA | Ask for price |
KRTAP1-4 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV-RFP-2A-Puro) |
|||
| LV730646 | ABM | 1.0 ug DNA | Ask for price |
KRTAP2-4 - Human, 4 unique 29mer shRNA constructs in lentiviral GFP vector |
|||
| TL319445 | Origene Technologies GmbH | 5 µg/vial | Ask for price |
Krtap1-4 - Mouse, 4 unique 29mer shRNA constructs in lentiviral GFP vector |
|||
| TL517621 | Origene Technologies GmbH | 5 µg/vial | Ask for price |
KRTAP9-4 - Human, 4 unique 29mer shRNA constructs in lentiviral GFP vector |
|||
| TL303605 | Origene Technologies GmbH | 5 µg/vial | Ask for price |
KRTAP4-4 - Human, 4 unique 29mer shRNA constructs in lentiviral GFP vector |
|||
| TL303606 | Origene Technologies GmbH | 5 µg/vial | Ask for price |
Krtap14 - Rat, 4 unique 29mer shRNA constructs in lentiviral GFP vector |
|||
| TL707828 | Origene Technologies GmbH | 5 µg/vial | Ask for price |
Krtap10-10 - Mouse, 4 unique 29mer shRNA constructs in lentiviral GFP vector |
|||
| TL517519 | Origene Technologies GmbH | 5 µg/vial | Ask for price |
KRTAP10-12 - Human, 4 unique 29mer shRNA constructs in lentiviral GFP vector |
|||
| TL303620 | Origene Technologies GmbH | 5 µg/vial | Ask for price |
KRTAP10-11 - Human, 4 unique 29mer shRNA constructs in lentiviral GFP vector |
|||
| TL303621 | Origene Technologies GmbH | 5 µg/vial | Ask for price |
KRTAP10-10 - Human, 4 unique 29mer shRNA constructs in lentiviral GFP vector |
|||
| TL303622 | Origene Technologies GmbH | 5 µg/vial | Ask for price |
Krtap13-2 - Rat, 4 unique 29mer shRNA constructs in lentiviral GFP vector |
|||
| TL707827 | Origene Technologies GmbH | 5 µg/vial | Ask for price |
Krtap16-5 - Rat, 4 unique 29mer shRNA constructs in lentiviral GFP vector |
|||
| TL707916 | Origene Technologies GmbH | 5 µg/vial | Ask for price |
Krtap15-1 - Rat, 4 unique 29mer shRNA constructs in lentiviral GFP vector |
|||
| TL704491 | Origene Technologies GmbH | 5 µg/vial | Ask for price |
KRTAP16-1 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV) |
|||
| LV730715 | ABM | 1.0 ug DNA | Ask for price |
KRTAP16-1 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV730719 | ABM | 1.0 ug DNA | Ask for price |
KRTAP29-1 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV) |
|||
| LV730739 | ABM | 1.0 ug DNA | Ask for price |
KRTAP29-1 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV730743 | ABM | 1.0 ug DNA | Ask for price |
KRTAP9-2 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV) |
|||
| LV706419 | ABM | 1.0 ug DNA | EUR 540 |
KRTAP9-2 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV706423 | ABM | 1.0 ug DNA | EUR 540 |
KRTAP9-6 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV) |
|||
| LV730685 | ABM | 1.0 ug DNA | Ask for price |
KRTAP9-6 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV730689 | ABM | 1.0 ug DNA | Ask for price |
KRTAP9-7 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV) |
|||
| LV730691 | ABM | 1.0 ug DNA | Ask for price |
KRTAP9-7 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV730695 | ABM | 1.0 ug DNA | Ask for price |
KRTAP2-3 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV) |
|||
| LV730649 | ABM | 1.0 ug DNA | Ask for price |
KRTAP2-3 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV730653 | ABM | 1.0 ug DNA | Ask for price |
Krtap13 - Mouse, 4 unique 29mer shRNA constructs in lentiviral GFP vector |
|||
| TL501219 | Origene Technologies GmbH | 5 µg/vial | Ask for price |
Krtap14 - Mouse, 4 unique 29mer shRNA constructs in lentiviral GFP vector |
|||
| TL513538 | Origene Technologies GmbH | 5 µg/vial | Ask for price |
Krtap15 - Mouse, 4 unique 29mer shRNA constructs in lentiviral GFP vector |
|||
| TL515189 | Origene Technologies GmbH | 5 µg/vial | Ask for price |
KRTAP27-1 - Human, 4 unique 29mer shRNA constructs in lentiviral GFP vector |
|||
| TL320832 | Origene Technologies GmbH | 5 µg/vial | Ask for price |
KRTAP24-1 - Human, 4 unique 29mer shRNA constructs in lentiviral GFP vector |
|||
| TL320970 | Origene Technologies GmbH | 5 µg/vial | Ask for price |
KRTAP19-8 - Human, 4 unique 29mer shRNA constructs in lentiviral GFP vector |
|||
| TL321035 | Origene Technologies GmbH | 5 µg/vial | Ask for price |
KRTAP20-3 - Human, 4 unique 29mer shRNA constructs in lentiviral GFP vector |
|||
| TL321215 | Origene Technologies GmbH | 5 µg/vial | Ask for price |
KRTAP25-1 - Human, 4 unique 29mer shRNA constructs in lentiviral GFP vector |
|||
| TL321221 | Origene Technologies GmbH | 5 µg/vial | Ask for price |
KRTAP22-1 - Human, 4 unique 29mer shRNA constructs in lentiviral GFP vector |
|||
| TL321519 | Origene Technologies GmbH | 5 µg/vial | Ask for price |
KRTAP15-1 - Human, 4 unique 29mer shRNA constructs in lentiviral GFP vector |
|||
| TL318160 | Origene Technologies GmbH | 5 µg/vial | Ask for price |
KRTAP19-2 - Human, 4 unique 29mer shRNA constructs in lentiviral GFP vector |
|||
| TL318340 | Origene Technologies GmbH | 5 µg/vial | Ask for price |
KRTAP20-1 - Human, 4 unique 29mer shRNA constructs in lentiviral GFP vector |
|||
| TL318341 | Origene Technologies GmbH | 5 µg/vial | Ask for price |
KRTAP23-1 - Human, 4 unique 29mer shRNA constructs in lentiviral GFP vector |
|||
| TL319442 | Origene Technologies GmbH | 5 µg/vial | Ask for price |
KRTAP21-1 - Human, 4 unique 29mer shRNA constructs in lentiviral GFP vector |
|||
| TL319443 | Origene Technologies GmbH | 5 µg/vial | Ask for price |
KRTAP20-2 - Human, 4 unique 29mer shRNA constructs in lentiviral GFP vector |
|||
| TL319444 | Origene Technologies GmbH | 5 µg/vial | Ask for price |
KRTAP19-3 - Human, 4 unique 29mer shRNA constructs in lentiviral GFP vector |
|||
| TL319446 | Origene Technologies GmbH | 5 µg/vial | Ask for price |
KRTAP19-5 - Human, 4 unique 29mer shRNA constructs in lentiviral GFP vector |
|||
| TL319448 | Origene Technologies GmbH | 5 µg/vial | Ask for price |
KRTAP19-6 - Human, 4 unique 29mer shRNA constructs in lentiviral GFP vector |
|||
| TL319449 | Origene Technologies GmbH | 5 µg/vial | Ask for price |
KRTAP19-7 - Human, 4 unique 29mer shRNA constructs in lentiviral GFP vector |
|||
| TL319450 | Origene Technologies GmbH | 5 µg/vial | Ask for price |
KRTAP17-1 - Human, 4 unique 29mer shRNA constructs in lentiviral GFP vector |
|||
| TL319451 | Origene Technologies GmbH | 5 µg/vial | Ask for price |
KRTAP12-2 - Human, 4 unique 29mer shRNA constructs in lentiviral GFP vector |
|||
| TL319452 | Origene Technologies GmbH | 5 µg/vial | Ask for price |
KRTAP12-1 - Human, 4 unique 29mer shRNA constructs in lentiviral GFP vector |
|||
| TL319453 | Origene Technologies GmbH | 5 µg/vial | Ask for price |
KRTAP12-3 - Human, 4 unique 29mer shRNA constructs in lentiviral GFP vector |
|||
| TL319454 | Origene Technologies GmbH | 5 µg/vial | Ask for price |
Krtap19-3 - Mouse, 4 unique 29mer shRNA constructs in lentiviral GFP vector |
|||
| TL505258 | Origene Technologies GmbH | 5 µg/vial | Ask for price |
Krtap19-2 - Mouse, 4 unique 29mer shRNA constructs in lentiviral GFP vector |
|||
| TL506055 | Origene Technologies GmbH | 5 µg/vial | Ask for price |
Krtap19-1 - Mouse, 4 unique 29mer shRNA constructs in lentiviral GFP vector |
|||
| TL506057 | Origene Technologies GmbH | 5 µg/vial | Ask for price |
Krtap4-13 - Mouse, 4 unique 29mer shRNA constructs in lentiviral GFP vector |
|||
| TL504309 | Origene Technologies GmbH | 5 µg/vial | Ask for price |
Krtap31-1 - Mouse, 4 unique 29mer shRNA constructs in lentiviral GFP vector |
|||
| TL504494 | Origene Technologies GmbH | 5 µg/vial | Ask for price |
Krtap16-3 - Mouse, 4 unique 29mer shRNA constructs in lentiviral GFP vector |
|||
| TL504542 | Origene Technologies GmbH | 5 µg/vial | Ask for price |
Krtap26-1 - Mouse, 4 unique 29mer shRNA constructs in lentiviral GFP vector |
|||
| TL517294 | Origene Technologies GmbH | 5 µg/vial | Ask for price |
Krtap4-16 - Mouse, 4 unique 29mer shRNA constructs in lentiviral GFP vector |
|||
| TL517509 | Origene Technologies GmbH | 5 µg/vial | Ask for price |
Krtap17-1 - Mouse, 4 unique 29mer shRNA constructs in lentiviral GFP vector |
|||
| TL518397 | Origene Technologies GmbH | 5 µg/vial | Ask for price |
Krtap11-1 - Mouse, 4 unique 29mer shRNA constructs in lentiviral GFP vector |
|||
| TL518704 | Origene Technologies GmbH | 5 µg/vial | Ask for price |
Krtap19-9b - Mouse, 4 unique 29mer shRNA constructs in lentiviral GFP vector |
|||
| TL519619 | Origene Technologies GmbH | 5 µg/vial | Ask for price |
Krtap31-2 - Mouse, 4 unique 29mer shRNA constructs in lentiviral GFP vector |
|||
| TL508782 | Origene Technologies GmbH | 5 µg/vial | Ask for price |
KRTAP19-1 - Human, 4 unique 29mer shRNA constructs in lentiviral GFP vector |
|||
| TL307822 | Origene Technologies GmbH | 5 µg/vial | Ask for price |
KRTAP10-7 - Human, 4 unique 29mer shRNA constructs in lentiviral GFP vector |
|||
| TL307901 | Origene Technologies GmbH | 5 µg/vial | Ask for price |
KRTAP10-9 - Human, 4 unique 29mer shRNA constructs in lentiviral GFP vector |
|||
| TL307902 | Origene Technologies GmbH | 5 µg/vial | Ask for price |
KRTAP10-5 - Human, 4 unique 29mer shRNA constructs in lentiviral GFP vector |
|||
| TL307903 | Origene Technologies GmbH | 5 µg/vial | Ask for price |
KRTAP26-1 - Human, 4 unique 29mer shRNA constructs in lentiviral GFP vector |
|||
| TL307945 | Origene Technologies GmbH | 5 µg/vial | Ask for price |
Krtap13-1 - Mouse, 4 unique 29mer shRNA constructs in lentiviral GFP vector |
|||
| TL516139 | Origene Technologies GmbH | 5 µg/vial | Ask for price |
Krtap12-1 - Mouse, 4 unique 29mer shRNA constructs in lentiviral GFP vector |
|||
| TL516748 | Origene Technologies GmbH | 5 µg/vial | Ask for price |
Krtap19-5 - Mouse, 4 unique 29mer shRNA constructs in lentiviral GFP vector |
|||
| TL509834 | Origene Technologies GmbH | 5 µg/vial | Ask for price |
Krtap21-1 - Mouse, 4 unique 29mer shRNA constructs in lentiviral GFP vector |
|||
| TL514547 | Origene Technologies GmbH | 5 µg/vial | Ask for price |
KRTAP4-12 - Human, 4 unique 29mer shRNA constructs in lentiviral GFP vector |
|||
| TL303607 | Origene Technologies GmbH | 5 µg/vial | Ask for price |
KRTAP21-2 - Human, 4 unique 29mer shRNA constructs in lentiviral GFP vector |
|||
| TL303609 | Origene Technologies GmbH | 5 µg/vial | Ask for price |
KRTAP13-3 - Human, 4 unique 29mer shRNA constructs in lentiviral GFP vector |
|||
| TL303611 | Origene Technologies GmbH | 5 µg/vial | Ask for price |
KRTAP13-2 - Human, 4 unique 29mer shRNA constructs in lentiviral GFP vector |
|||
| TL303612 | Origene Technologies GmbH | 5 µg/vial | Ask for price |
KRTAP13-1 - Human, 4 unique 29mer shRNA constructs in lentiviral GFP vector |
|||
| TL303613 | Origene Technologies GmbH | 5 µg/vial | Ask for price |
KRTAP11-1 - Human, 4 unique 29mer shRNA constructs in lentiviral GFP vector |
|||
| TL303614 | Origene Technologies GmbH | 5 µg/vial | Ask for price |
KRTAP10-8 - Human, 4 unique 29mer shRNA constructs in lentiviral GFP vector |
|||
| TL303616 | Origene Technologies GmbH | 5 µg/vial | Ask for price |
KRTAP10-6 - Human, 4 unique 29mer shRNA constructs in lentiviral GFP vector |
|||
| TL303617 | Origene Technologies GmbH | 5 µg/vial | Ask for price |
KRTAP10-3 - Human, 4 unique 29mer shRNA constructs in lentiviral GFP vector |
|||
| TL303618 | Origene Technologies GmbH | 5 µg/vial | Ask for price |
KRTAP10-2 - Human, 4 unique 29mer shRNA constructs in lentiviral GFP vector |
|||
| TL303619 | Origene Technologies GmbH | 5 µg/vial | Ask for price |
KRTAP10-1 - Human, 4 unique 29mer shRNA constructs in lentiviral GFP vector |
|||
| TL303623 | Origene Technologies GmbH | 5 µg/vial | Ask for price |
KRTAP16-1 Lentiviral Vector (Human) (EF1a) (pLenti-GIII-EF1a) |
|||
| LV730720 | ABM | 1.0 ug DNA | Ask for price |
KRTAP29-1 Lentiviral Vector (Human) (EF1a) (pLenti-GIII-EF1a) |
|||
| LV730744 | ABM | 1.0 ug DNA | Ask for price |
Krtap7-1 - Rat, 4 unique 29mer shRNA constructs in lentiviral GFP vector |
|||
| TL709119 | Origene Technologies GmbH | 5 µg/vial | Ask for price |
Krtap1-5 - Rat, 4 unique 29mer shRNA constructs in lentiviral GFP vector |
|||
| TL702877 | Origene Technologies GmbH | 5 µg/vial | Ask for price |
KRTAP10-13P Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV) |
|||
| LV730697 | ABM | 1.0 ug DNA | Ask for price |
KRTAP10-13P Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV730701 | ABM | 1.0 ug DNA | Ask for price |
KRTAP19-10P Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV) |
|||
| LV730727 | ABM | 1.0 ug DNA | Ask for price |
KRTAP19-10P Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV730731 | ABM | 1.0 ug DNA | Ask for price |
KRTAP19-11P Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV) |
|||
| LV730733 | ABM | 1.0 ug DNA | Ask for price |
KRTAP19-11P Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV730737 | ABM | 1.0 ug DNA | Ask for price |
KRTAP9-2 Lentiviral Vector (Human) (EF1a) (pLenti-GIII-EF1a) |
|||
| LV706424 | ABM | 1.0 ug DNA | EUR 540 |
KRTAP9-6 Lentiviral Vector (Human) (EF1a) (pLenti-GIII-EF1a) |
|||
| LV730690 | ABM | 1.0 ug DNA | Ask for price |
KRTAP9-7 Lentiviral Vector (Human) (EF1a) (pLenti-GIII-EF1a) |
|||
| LV730696 | ABM | 1.0 ug DNA | Ask for price |
KRTAP2-3 Lentiviral Vector (Human) (EF1a) (pLenti-GIII-EF1a) |
|||
| LV730654 | ABM | 1.0 ug DNA | Ask for price |
KRTAP4-16P Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV) |
|||
| LV766493 | ABM | 1.0 ug DNA | Ask for price |
KRTAP4-16P Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV766497 | ABM | 1.0 ug DNA | Ask for price |
KRTAP9-11P Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV) |
|||
| LV766499 | ABM | 1.0 ug DNA | Ask for price |
KRTAP9-11P Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV766503 | ABM | 1.0 ug DNA | Ask for price |
KRTAP21-4P Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV) |
|||
| LV766505 | ABM | 1.0 ug DNA | Ask for price |
KRTAP21-4P Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV766509 | ABM | 1.0 ug DNA | Ask for price |
KRTAP13-5P Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV) |
|||
| LV730703 | ABM | 1.0 ug DNA | Ask for price |
KRTAP13-5P Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV730707 | ABM | 1.0 ug DNA | Ask for price |
KRTAP13-6P Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV) |
|||
| LV730709 | ABM | 1.0 ug DNA | Ask for price |
KRTAP13-6P Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV730713 | ABM | 1.0 ug DNA | Ask for price |
KRTAP19-9P Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV) |
|||
| LV730721 | ABM | 1.0 ug DNA | Ask for price |
KRTAP19-9P Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV730725 | ABM | 1.0 ug DNA | Ask for price |
KRTAP10-13P Lentiviral Vector (Human) (EF1a) (pLenti-GIII-EF1a) |
|||
| LV730702 | ABM | 1.0 ug DNA | Ask for price |
KRTAP19-10P Lentiviral Vector (Human) (EF1a) (pLenti-GIII-EF1a) |
|||
| LV730732 | ABM | 1.0 ug DNA | Ask for price |
KRTAP19-11P Lentiviral Vector (Human) (EF1a) (pLenti-GIII-EF1a) |
|||
| LV730738 | ABM | 1.0 ug DNA | Ask for price |
KRTAP2-1 - Human, 4 unique 29mer shRNA constructs in lentiviral GFP vector |
|||
| TL321192 | Origene Technologies GmbH | 5 µg/vial | Ask for price |
KRTAP9-9 - Human, 4 unique 29mer shRNA constructs in lentiviral GFP vector |
|||
| TL321486 | Origene Technologies GmbH | 5 µg/vial | Ask for price |
KRTAP9-8 - Human, 4 unique 29mer shRNA constructs in lentiviral GFP vector |
|||
| TL321488 | Origene Technologies GmbH | 5 µg/vial | Ask for price |
KRTAP2-2 - Human, 4 unique 29mer shRNA constructs in lentiviral GFP vector |
|||
| TL321493 | Origene Technologies GmbH | 5 µg/vial | Ask for price |
KRTAP4-3 - Human, 4 unique 29mer shRNA constructs in lentiviral GFP vector |
|||
| TL321495 | Origene Technologies GmbH | 5 µg/vial | Ask for price |
KRTAP1-3 - Human, 4 unique 29mer shRNA constructs in lentiviral GFP vector |
|||
| TL317563 | Origene Technologies GmbH | 5 µg/vial | Ask for price |
KRTAP1-5 - Human, 4 unique 29mer shRNA constructs in lentiviral GFP vector |
|||
| TL317589 | Origene Technologies GmbH | 5 µg/vial | Ask for price |
KRTAP3-1 - Human, 4 unique 29mer shRNA constructs in lentiviral GFP vector |
|||
| TL317590 | Origene Technologies GmbH | 5 µg/vial | Ask for price |
KRTAP9-3 - Human, 4 unique 29mer shRNA constructs in lentiviral GFP vector |
|||
| TL317591 | Origene Technologies GmbH | 5 µg/vial | Ask for price |
KRTAP8-1 - Human, 4 unique 29mer shRNA constructs in lentiviral GFP vector |
|||
| TL318338 | Origene Technologies GmbH | 5 µg/vial | Ask for price |
KRTAP6-2 - Human, 4 unique 29mer shRNA constructs in lentiviral GFP vector |
|||
| TL318339 | Origene Technologies GmbH | 5 µg/vial | Ask for price |
KRTAP9-2 - Human, 4 unique 29mer shRNA constructs in lentiviral GFP vector |
|||
| TL319424 | Origene Technologies GmbH | 5 µg/vial | Ask for price |
KRTAP7-1 - Human, 4 unique 29mer shRNA constructs in lentiviral GFP vector |
|||
| TL319425 | Origene Technologies GmbH | 5 µg/vial | Ask for price |
KRTAP6-1 - Human, 4 unique 29mer shRNA constructs in lentiviral GFP vector |
|||
| TL319426 | Origene Technologies GmbH | 5 µg/vial | Ask for price |
KRTAP6-3 - Human, 4 unique 29mer shRNA constructs in lentiviral GFP vector |
|||
| TL319427 | Origene Technologies GmbH | 5 µg/vial | Ask for price |
KRTAP4-5 - Human, 4 unique 29mer shRNA constructs in lentiviral GFP vector |
|||
| TL319438 | Origene Technologies GmbH | 5 µg/vial | Ask for price |
KRTAP4-2 - Human, 4 unique 29mer shRNA constructs in lentiviral GFP vector |
|||
| TL319439 | Origene Technologies GmbH | 5 µg/vial | Ask for price |
KRTAP3-2 - Human, 4 unique 29mer shRNA constructs in lentiviral GFP vector |
|||
| TL319440 | Origene Technologies GmbH | 5 µg/vial | Ask for price |
KRTAP3-3 - Human, 4 unique 29mer shRNA constructs in lentiviral GFP vector |
|||
| TL319441 | Origene Technologies GmbH | 5 µg/vial | Ask for price |
Krtap6-5 - Mouse, 4 unique 29mer shRNA constructs in lentiviral GFP vector |
|||
| TL504158 | Origene Technologies GmbH | 5 µg/vial | Ask for price |
Krtap4-1 - Mouse, 4 unique 29mer shRNA constructs in lentiviral GFP vector |
|||
| TL517683 | Origene Technologies GmbH | 5 µg/vial | Ask for price |
Krtap1-3 - Mouse, 4 unique 29mer shRNA constructs in lentiviral GFP vector |
|||
| TL518296 | Origene Technologies GmbH | 5 µg/vial | Ask for price |
Krtap9-5 - Mouse, 4 unique 29mer shRNA constructs in lentiviral GFP vector |
|||
| TL518297 | Origene Technologies GmbH | 5 µg/vial | Ask for price |
Krtap4-8 - Mouse, 4 unique 29mer shRNA constructs in lentiviral GFP vector |
|||
| TL518316 | Origene Technologies GmbH | 5 µg/vial | Ask for price |
Krtap4-9 - Mouse, 4 unique 29mer shRNA constructs in lentiviral GFP vector |
|||
| TL518317 | Origene Technologies GmbH | 5 µg/vial | Ask for price |
Krtap6-1 - Mouse, 4 unique 29mer shRNA constructs in lentiviral GFP vector |
|||
| TL519066 | Origene Technologies GmbH | 5 µg/vial | Ask for price |
Krtap3-3 - Mouse, 4 unique 29mer shRNA constructs in lentiviral GFP vector |
|||
| TL519284 | Origene Technologies GmbH | 5 µg/vial | Ask for price |
Krtap3-2 - Mouse, 4 unique 29mer shRNA constructs in lentiviral GFP vector |
|||
| TL519301 | Origene Technologies GmbH | 5 µg/vial | Ask for price |
Krtap4-6 - Mouse, 4 unique 29mer shRNA constructs in lentiviral GFP vector |
|||
| TL519353 | Origene Technologies GmbH | 5 µg/vial | Ask for price |
Krtap1-5 - Mouse, 4 unique 29mer shRNA constructs in lentiviral GFP vector |
|||
| TL519380 | Origene Technologies GmbH | 5 µg/vial | Ask for price |
Krtap7-1 - Mouse, 4 unique 29mer shRNA constructs in lentiviral GFP vector |
|||
| TL519419 | Origene Technologies GmbH | 5 µg/vial | Ask for price |
Krtap9-3 - Mouse, 4 unique 29mer shRNA constructs in lentiviral GFP vector |
|||
| TL519508 | Origene Technologies GmbH | 5 µg/vial | Ask for price |
Krtap6-2 - Mouse, 4 unique 29mer shRNA constructs in lentiviral GFP vector |
|||
| TL515208 | Origene Technologies GmbH | 5 µg/vial | Ask for price |
Krtap4-2 - Mouse, 4 unique 29mer shRNA constructs in lentiviral GFP vector |
|||
| TL515382 | Origene Technologies GmbH | 5 µg/vial | Ask for price |
Krtap9-1 - Mouse, 4 unique 29mer shRNA constructs in lentiviral GFP vector |
|||
| TL517157 | Origene Technologies GmbH | 5 µg/vial | Ask for price |
Krtap4-7 - Mouse, 4 unique 29mer shRNA constructs in lentiviral GFP vector |
|||
| TL513840 | Origene Technologies GmbH | 5 µg/vial | Ask for price |
KRTAP4-1 - Human, 4 unique 29mer shRNA constructs in lentiviral GFP vector |
|||
| TL303608 | Origene Technologies GmbH | 5 µg/vial | Ask for price |
KRTAP1-1 - Human, 4 unique 29mer shRNA constructs in lentiviral GFP vector |
|||
| TL303615 | Origene Technologies GmbH | 5 µg/vial | Ask for price |
KRTAP4-16P Lentiviral Vector (Human) (EF1a) (pLenti-GIII-EF1a) |
|||
| LV766498 | ABM | 1.0 ug DNA | Ask for price |
KRTAP9-11P Lentiviral Vector (Human) (EF1a) (pLenti-GIII-EF1a) |
|||
| LV766504 | ABM | 1.0 ug DNA | Ask for price |
KRTAP21-4P Lentiviral Vector (Human) (EF1a) (pLenti-GIII-EF1a) |
|||
| LV766510 | ABM | 1.0 ug DNA | Ask for price |
KRTAP13-5P Lentiviral Vector (Human) (EF1a) (pLenti-GIII-EF1a) |
|||
| LV730708 | ABM | 1.0 ug DNA | Ask for price |
KRTAP13-6P Lentiviral Vector (Human) (EF1a) (pLenti-GIII-EF1a) |
|||
| LV730714 | ABM | 1.0 ug DNA | Ask for price |
KRTAP19-9P Lentiviral Vector (Human) (EF1a) (pLenti-GIII-EF1a) |
|||
| LV730726 | ABM | 1.0 ug DNA | Ask for price |
These outcomes present {that a} single injection with focused lentiviral vectors might be an efficient immunotherapy for breast most cancers. Moreover, they could possibly be mixed with different immunotherapeutic regimens to enhance outcomes for sufferers with breast most cancers.
